Literature DB >> 12944064

Nephrotic syndrome in childhood.

Allison A Eddy1, Jordan M Symons.   

Abstract

Childhood nephrotic syndromes are most commonly caused by one of two idiopathic diseases: minimal-change nephrotic syndrome (MCNS) and focal segmental glomerulosclerosis (FSGS). A third distinct type, membranous nephropathy, is rare in children. Other causes of isolated nephrotic syndrome can be subdivided into two major categories: rare genetic disorders, and secondary diseases associated with drugs, infections, or neoplasia. The cause of idiopathic nephrotic syndrome remains unknown, but evidence suggests it may be a primary T-cell disorder that leads to glomerular podocyte dysfunction. Genetic studies in children with familial nephrotic syndrome have identified mutations in genes that encode important podocyte proteins. Patients with idiopathic nephrotic syndrome are initially treated with corticosteroids. Steroid-responsiveness is of greater prognostic use than renal histology. Several second-line drugs, including alkylating agents, ciclosporin, and levamisole, may be effective for complicated and steroid-unresponsive MCNS and FSGS patients. Nephrotic syndrome is associated with several medical complications, the most severe and potentially fatal being bacterial infections and thromboembolism. Idiopathic nephrotic syndrome is a chronic relapsing disease for most steroid-responsive patients, whereas most children with refractory FSGS ultimately develop end-stage renal disease. Research is being done to further elucidate the disorder's molecular pathogenesis, identify new prognostic indicators, and to develop better approaches to treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944064     DOI: 10.1016/S0140-6736(03)14184-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  275 in total

1.  Is cyclophosphamide effective in patients with IgM-positive minimal change disease?

Authors:  Pavel Geier; Amani Roushdi; Sylva Skálová; Jennifer Vethamuthu; Gabrielle Weiler; Janusz Feber
Journal:  Pediatr Nephrol       Date:  2012-06-24       Impact factor: 3.714

2.  Genetic abnormalities and prognosis in patients with congenital and infantile nephrotic syndrome.

Authors:  Onur Cil; Nesrin Besbas; Ali Duzova; Rezan Topaloglu; Amira Peco-Antić; Emine Korkmaz; Fatih Ozaltin
Journal:  Pediatr Nephrol       Date:  2015-02-27       Impact factor: 3.714

3.  Differential risk of remission and ESRD in childhood FSGS.

Authors:  Debbie S Gipson; Hyunsook Chin; Trevor P Presler; Caroline Jennette; Maria E Ferris; Susan Massengill; Keisha Gibson; David B Thomas
Journal:  Pediatr Nephrol       Date:  2006-01-05       Impact factor: 3.714

4.  Pathological profile of biopsied Egyptian children with primary nephrotic syndrome: 15-year single center experience.

Authors:  Ashraf Bakr; Riham Eid; Amr Sarhan; Ayman Hammad; Ahmed Mahmoud El-Refaey; Atef El-Mougy; Mohammed Magdy Zedan; Fatma Moustafa; Ashraf Abdelrahman
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

5.  Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1α and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway.

Authors:  Ahmad K Mashmoushi; Jim C Oates
Journal:  Free Radic Biol Med       Date:  2015-03-09       Impact factor: 7.376

6.  Low birth weight, but not postnatal weight gain, aggravates the course of nephrotic syndrome.

Authors:  Christian Plank; Iris Ostreicher; Katalin Dittrich; Rüdiger Waldherr; Manfred Voigt; Kerstin Amann; Wolfgang Rascher; Jörg Dötsch
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

7.  Pulmonary thrombosis as the first manifestation of systemic lupus erythematosus in a 14-year-old boy.

Authors:  Annie Harroche; Natascha Remus; Solenn Gaubicher; Olivier Dunand; Magali Colombat; Christophe Delacourt; Fouad Madhi
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

8.  Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome.

Authors:  Hélène Lapillonne; Annelaure Leclerc; Tim Ulinski; Laurent Balu; Arnaud Garnier; Nathalie Dereuddre-Bosquet; Hervé Watier; Marie-Hélène Schlageter; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2008-05-06       Impact factor: 3.714

9.  Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome.

Authors:  Mukta Mantan; Chenni S Sriram; Pankaj Hari; Amit Dinda; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

Review 10.  Treatment of steroid-resistant nephrotic syndrome in the genomic era.

Authors:  Adam R Bensimhon; Anna E Williams; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2018-10-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.